Investment Trusts
Worldwide Healthcare Trust is a global investment trust focused on pharmaceutical, biotechnology, medical-device and healthcare-services companies. It invests across both established large companies and smaller innovative businesses to capture long-term growth in healthcare.
Global healthcare equity investment, biotechnology and pharmaceutical stock selection, exposure to medical technology and services, gearing and dividend distributions.
Global healthcare markets, with particularly large exposure to the United States and additional investments across Europe, Japan and emerging markets.
Drug approvals, clinical trial results, healthcare M&A, pharmaceutical pipelines, medical innovation, sector valuations, stock selection and the trust's discount to NAV.
Clinical trial failures, drug-pricing regulation, patent expiries, biotechnology volatility, political healthcare reform, concentrated sector exposure and discount widening.
FY2026 results showed a strong NAV total return of around 10%, comfortably ahead of the healthcare benchmark, aided by stock selection and improving sector sentiment. Healthcare M&A, biotechnology funding conditions and regulatory policy remain important catalysts, while the managers continue to balance large pharmaceutical holdings with smaller innovation-led companies into 2027.
WWH pays a modest semi-annual dividend because capital growth is the main objective. The FY2026 interim dividend was 0.7p per share and the 1.7p final dividend went ex-dividend on 11 June 2026 and was paid in July, giving a 2.4p full-year total.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.